Phaseline

Targets › CSFL1R

CSFL1R: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on CSFL1R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Wei ZhaoPEGylated Recombinant Human Granulocyte Colony-Stimulating Factor
G-CSF receptor agonist
CSFL1RPhase 4Hematological NeoplasmsDec 2026

Conditions

Hematological Neoplasms (1)

Modalities

mixed (1)

Companies

Wei Zhao (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.